Abcam plc (A8C3.F)
| Chiusura precedente | 13,00 |
| Aperto | 13,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 12,80 - 12,80 |
| Intervallo di 52 settimane | 11,70 - 20,80 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | 3,049B |
| Beta (5 anni mensile) | 0,71 |
| Rapporto PE (ttm) | 590,91 |
| EPS (ttm) | 0,02 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1.702,05 |
- GlobeNewswire
Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021
Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting refe
- GlobeNewswire
Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
As an element of Nautilus’ overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam’s antibody development technology and expertiseSEATTLE and CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global
- GlobeNewswire
29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases
CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month period. SUMMARY PERFORMANCE 12 mont
